Quest Diagnostics Incorporated (DGX) — Q2 2021 Form 10-Q
Business context and reporting period. The filing covers the quarter and six months ended June 30, 2021. Quest’s Diagnostic Information Services (DIS)—clinical, anatomic pathology, and related testing—generated 97% of quarterly revenue; Diagnostic Solutions accounted for the balance. Results remained materially affected by the COVID-19 pandemic and comparisons with the disrupted 2020 period.
Financial performance
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $2.550 billion | $1.827 billion | $5.270 billion | $3.649 billion |
| Operating income | $533 million | $283 million | $1.193 billion | $458 million |
| Operating margin | 20.9% | 15.5% | 22.6% | 12.5% |
| Net income attributable to Quest | $631 million | $185 million | $1.100 billion | $284 million |
| Diluted EPS | $4.96 | $1.36 | $8.38 | $2.09 |
| Operating cash flow | $460 million | $355 million | $1.191 billion | $602 million |
Revenue mix and operating trends. Q2 DIS revenue rose 40.2% to $2.474 billion; requisition volume increased 45.2%, while revenue per requisition fell 3.6%, partly reflecting lower-revenue-per-requisition Professional Laboratory Services engagements and acquisitions. Q2 service revenue included $1.150 billion routine clinical testing, $511 million COVID-19 testing, $673 million gene-based and esoteric testing, and $140 million anatomic pathology. Operating income increased faster than revenue, with operating margin up to 20.9% from 15.5%.
Cash, debt, and liquidity. At June 30, cash and cash equivalents were $560 million, down from $1.158 billion at year-end. Long-term debt was $4.008 billion, with $2 million current; total debt carrying value was approximately $4.010 billion. Six-month investing cash flow was positive $344 million, including proceeds from the Q2 Solutions sale; financing cash outflow was $2.133 billion, chiefly reflecting share repurchases. Quest had $1.3 billion available under credit facilities, no borrowings under those facilities, and reported compliance with applicable covenants. Management said cash, operating cash flow, and available borrowing capacity should fund expected needs for the foreseeable future.
Material changes and unusual items
- Q2 revenue increased 39.5% year over year, but the comparison reflects pandemic-related disruption to the 2020 base period. For Q2 2021, base testing volume excluding recent acquisitions was 1.9% above Q2 2019; first-half base volume on the same basis remained 0.4% below the first half of 2019.
- Quest sold its 40% Q2 Solutions joint-venture interest to IQVIA on April 1 for $760 million cash and recorded a $314 million pretax gain. This gain contributed $2.04 to Q2 diluted EPS; management said listed items together increased Q2 diluted EPS by $1.78. Reported earnings therefore include a material nonrecurring gain.
- In June, Quest acquired Mercy Health’s outreach laboratory services business for $225 million cash, primarily recording $171 million of goodwill and $54 million of customer-related intangible assets.
- Quest repurchased 12.5 million shares for $1.6 billion in the first half, including a $1.5 billion accelerated share repurchase. The ASRs initially delivered 9.1 million shares; settlement of the remaining shares was expected in the third and fourth quarters of 2021. The repurchases reduced weighted-average shares and benefited EPS.
- Quarterly dividends declared increased to $0.62 per share in 2021 from $0.56 in 2020. Six-month capital expenditures were $170 million.
- For comparison, 2020 results included $65 million of CARES Act provider funds recognized in Q2; the income was reversed later in 2020 and the funds returned.
Outlook, risks, and contingencies
- Management expected continued return to healthcare during 2021, subject to pandemic conditions, and expected COVID-19 molecular testing demand to decline in the second half of 2021. COVID-19 testing revenue had fallen 55.7% in Q2 versus Q4 2020.
- Management estimated approximately $400 million of 2021 capital expenditures. Its Invigorate cost program targets annual savings of approximately 3% of costs; Quest recorded $34 million of related pretax charges in the first half and said additional restructuring charges may occur.
- Key uncertainties include pandemic severity and duration, testing reimbursement rates, payer and customer trends, supply-chain conditions, competition, regulation, and government investigations and litigation.
- Legal matters include a 401(k) plan class action for which a motion to dismiss was denied in May 2021, and litigation and government inquiries related to the AMCA data-security incident. Quest said material legal losses were not probable as of June 30, while noting outcomes could affect results or cash flows. Legal reserves were $6 million; general and professional liability reserves were $151 million.
- No full-year earnings or revenue guidance is provided in the supplied filing text. Interim results may not indicate full-year performance.
Important facts for investors to verify
- How much of reported earnings growth reflects recurring testing operations versus the $314 million Q2 Solutions gain, pandemic comparisons, and share-count reductions.
- Whether base-business volumes and revenue per requisition sustain improvement as COVID-19 testing demand and reimbursement rates change.
- Final ASR settlement, remaining repurchase authorization, and the effects of capital returns on cash and debt capacity.
- Progress on the Mercy Health integration, Invigorate savings, and management’s approximately $400 million 2021 capital-spending estimate.
- Developments in the disclosed legal matters, investigations, and liability claims, for which ultimate outcomes and potential losses remain uncertain.